Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

FMC7 is an epitope of CD20.

Deans JP, Polyak MJ.

Blood. 2008 Feb 15;111(4):2492; author reply 2493-4. doi: 10.1182/blood-2007-11-126243. No abstract available.

2.
3.

A cholesterol-dependent CD20 epitope detected by the FMC7 antibody.

Polyak MJ, Ayer LM, Szczepek AJ, Deans JP.

Leukemia. 2003 Jul;17(7):1384-9.

PMID:
12835728
4.

Diagnostic significance of CD20 and FMC7 expression in B-cell disorders.

Delgado J, Matutes E, Morilla AM, Morilla RM, Owusu-Ankomah KA, Rafiq-Mohammed F, del Giudice I, Catovsky D.

Am J Clin Pathol. 2003 Nov;120(5):754-9.

PMID:
14608903
5.

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.

Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.

Cancer Sci. 2009 Jan;100(1):54-61. doi: 10.1111/j.1349-7006.2008.01005.x. Epub 2008 Nov 25.

6.

CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.

Kinoshita T, Nagai H, Murate T, Saito H.

J Clin Oncol. 1998 Dec;16(12):3916. No abstract available.

PMID:
9850038
7.

New monoclonal antibody approved as lymphoma therapy.

[No authors listed]

Am J Health Syst Pharm. 1998 Jan 15;55(2):110. No abstract available.

PMID:
9465971
8.

Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.

Kollmar O, Becker S, Schilling MK, Maurer CA.

Transplantation. 2002 Feb 27;73(4):669-70. No abstract available.

PMID:
11889454
9.

Immunotherapy with anti-CD20 compounds.

von Schilling C.

Semin Cancer Biol. 2003 Jun;13(3):211-22. Review.

PMID:
12959352
10.

[Resistance to rituximab and CD20 mutation].

Terui Y, Hatake K.

Nihon Rinsho. 2007 Jan 28;65 Suppl 1:416-23. Review. Japanese. No abstract available.

PMID:
17474440
11.

[First monoclonal antibody accepted for cancer therapy].

Itälä M.

Duodecim. 1998;114(6):509, 511. Finnish. No abstract available.

PMID:
11466914
12.

CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).

Yokose N, Shioi Y, Sugisaki Y, Ohaki Y, Ogata K, Dan K.

Leuk Lymphoma. 2006 Jul;47(7):1415-7. No abstract available.

PMID:
16923582
13.

Rituximab is effective for human herpesvirus-8-negative primary effusion lymphoma with CD20 phenotype associated hepatitis C virus-related liver cirrhosis.

Takao T, Kobayashi Y, Kuroda J, Omoto A, Nishimura T, Kamitsuji Y, Fukiya E, Nakamura C, Kimura S, Yoshikawa T.

Am J Hematol. 2004 Dec;77(4):419-20. No abstract available.

14.

[Rituximab resistance in B-cell lymphoma and its elimination].

Hatake K, Terui Y.

Gan To Kagaku Ryoho. 2009 Apr;36(4):548-51. Japanese.

PMID:
19381025
15.

[Monoclonal anti-CD20 antibody therapy].

Juhel L, Solal-Celigny P.

Rev Prat. 2004 Apr 15;54(7):711-2. French. No abstract available.

PMID:
15253285
16.

Bone marrow experts are still debating the value of purging.

Benowitz S.

J Natl Cancer Inst. 2000 Feb 2;92(3):190-2. No abstract available.

PMID:
10655432
17.

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death.

Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L, Introna M.

Blood. 2010 Oct 28;116(17):3372-3; author reply 3373-4. doi: 10.1182/blood-2010-06-289736. No abstract available.

18.

Anti-CD20 antibody therapy for B-cell lymphomas.

Calcagno A, Rostagno R, Di Perri G.

N Engl J Med. 2012 Aug 30;367(9):877-8; author reply 878. doi: 10.1056/NEJMc1207378#SA3. No abstract available.

PMID:
22931340
19.

Anti-CD20 antibody therapy for B-cell lymphomas.

El Fassi D, Hegedüs L, Nielsen CH.

N Engl J Med. 2012 Aug 30;367(9):877; author reply 878. doi: 10.1056/NEJMc1207378#SA2. No abstract available.

PMID:
22931339
20.

Anti-CD20 antibody therapy for B-cell lymphomas.

Taylor RP, Lindorfer MA, Zent CS.

N Engl J Med. 2012 Aug 30;367(9):876-7; author reply 878. doi: 10.1056/NEJMc1207378#SA1. No abstract available.

PMID:
22931338

Supplemental Content

Support Center